bluuebunny/crossref_metadata_2025_split huggingface dataset:
825-P: Composite Glucose and C-Peptide Endpoints Show Early Efficacy in Recent-Onset Type 1 Diabetes (T1D) Clinical Trials
Authors: JACOBSEN LAURA M. , CUTHBERTSON DAVID D. , HALLER MICHAEL J. , ISMAIL HEBA M. , SIMS EMILY K. , GITELMAN STEPHEN E. , WHERRETT DIANE K. , MORAN ANTOINETTE , ATKINSON MARK A. , PUGLIESE ALBERTO , GOTTLIEB PETER , SOSENKO JAY 
Published: May 2022

C-peptide area under the curve (AUC) at ≥1 year, a standard endpoint of recent-onset T1D clinical trials, is derived from a 120-minute mixed meal tolerance test (MMTT) . We analyzed whether composite glucose and C-peptide endpoints, useful in post hoc analyses of prevention trials, could detect treatment effects as early as 3 months between the combined treated and placebo groups from 3 TrialNet recent-onset T1D trials that met their primary endpoint. Comparisons were made between treated and placebo groups after adjustments for age, sex, and BMI Z-score using AUC C-peptide (standard measure) , AUC C-peptide/AUC glucose (AUC ratio) , and a new measure, the centroid ratio. Centroids, geometric central points of shapes, were derived from MMTT shapes formed from mean glucose and C-peptide values at 30, 60, 90, and 120 minutes. The centroid ratio is the C-peptide coordinate/glucose coordinate of the centroid. A treatment effect at 3 months was evident for centroid and AUC ratios (p&lt;0.0 and p=0.002, respectively) and not AUC C-peptide (p=0.056) . Similar results were seen when individual trials were compared. The difference between combined groups at 3, 6, and 12 months is demonstrated by vectors that start at baseline (Figure) .
In conclusion, composite glucose and C-peptide endpoints appear to identify early treatment efficacy and should be considered in future new-onset pilot studies and trials.

Disclosure
L.M.Jacobsen: None. A.Pugliese: Advisory Panel; Provention Bio, Inc., Consultant; Quell Tx. P.Gottlieb: Advisory Panel; Janssen Research & Development, LLC, ViaCyte, Inc., Other Relationship; IM Therapeutics, Research Support; Caladrius Biosciences, Inc., Immune Tolerance Network, National Institute of Diabetes and Digestive and Kidney Diseases, Novo Nordisk, Precigen, Inc., Tolerion, Inc. J.Sosenko: None. D.D.Cuthbertson: None. M.J.Haller: Advisory Panel; SAB Biotherapeutics , Consultant; MannKind Corporation, Sanofi. H.M.Ismail: n/a. E.K.Sims: Other Relationship; Medscape, Patent. S.E.Gitelman: Advisory Panel; Abata Therapeutics, Avotres Inc., Biolojic Design, Ltd., Provention Bio, Inc., Rubius, SAB Biotherapeutics, Inc., Tolerion, Inc. D.K.Wherrett: n/a. A.Moran: Advisory Panel; Dompé, Other Relationship; Novo Nordisk, Research Support; Abbott Diabetes, Provention Bio, Inc. M.A.Atkinson: None.
831-P: Tocilizumab Is Effective in Reducing Inflammation in T2D–COVID-Organ-on-a-Chip Model
Authors: NEGI VINNY , GAVLOCK DILLON , LEE JEONGKYUNG , SHUN TONGYING , GOUGH ALBERT , MIEDEL MARK T. , TAYLOR D. LANSING L. , YECHOOR VIJAY 
Published: May 2022

The COVID-pandemic has contributed to more than 5 million deaths worldwide in the last two years. Co-morbid conditions such as Type 2 Diabetes (T2D) , HTN, obesity, and CKD have been associated with increased mortality with COVID-19. In a large meta-analysis, the relative risk of mortality was 1.54 for patients with T2D and COVID-19. Thus, there is an imperative need to develop a platform for rapid and reliable drug screening/selection against COVID-related morbidity/mortality in T2D patients. With limited translatability of in vitro and small animal models to humans, human organ-on-a-chip models are an attractive platform to model in vivo disease conditions and test potential therapeutics. We seeded T2D or nondiabetes patient-derived macrophage and human liver sinusoidal endothelial cells along with normal hepatocytes and kupffer cells in the liver-on-a-chip (LAMPS - Liver Acinus MicroPhysiological System) developed by our group, perfused with media mimicking normal fasting or late metabolic syndrome (LMS - high levels of glucose, fatty acids, insulin, glucagon) states. We transduced both macrophage and endothelial cells to overexpress the SARS-CoV2-S (spike) protein and compared it with a control lentivirus transduction. We found that T2D cells overexpressing S-protein in LMS media (T2D chip) displayed an increased secretion of inflammatory cytokines compared to the nondiabetes chip over days. We then tested the effect of Tocilizumab (IL6-receptor antagonist) in T2D chips. Compared to vehicle control, Tocilizumab significantly decreased the S-protein induced inflammatory cytokine secretion in T2D chips but not in nondiabetes chips, indicating its higher efficacy in severe disease states only. This is consistent with what was observed in large clinical trials providing confirmatory evidence that the LAMPS T2D and nondiabetes chips serve as a relevant in vitro model system to replicate human in vivo pathophysiology of COVID and for screening potential therapeutics.

Disclosure
V.Negi: None. D.Gavlock: None. J.Lee: None. T.Shun: None. A.Gough: None. M.T.Miedel: None. D.L.Taylor: None. V.Yechoor: n/a.
835-P: The Hepatoselective Glucokinase Activator (GKA) TTP399 Does Not Increase Risk of Ketoacidosis in Type 1 Diabetes (T1D)
Authors: KLEIN KLARA , BOEDER SCHAFER C. , FREEMAN JENNIFER L. , MADDURI SUPRADEEP , GIOVANNETTI ERIN R. , VALCARCE CARMEN , BUSE JOHN B. , PETTUS JEREMY 
Published: May 2022

Identification of adjunctive, oral pharmacotherapies to treat T1D has been limited by risk of DKA. TTP399, an oral hepatoselective GKA, significantly improves glycemia in individuals with T1D compared to placebo. This double-blind, randomized, placebo-controlled, Phase 1 mechanistic study examined whether TTP399 decreases ketogenesis during insulin withdrawal.
Individuals with T1D (n=23) using insulin pump therapy were randomized to TTP399 or placebo for 7-days after which an insulin withdrawal test (IWT) was performed. Insulin pumps were disconnected for up to hours to induce ketogenesis.
TTP399 significantly reduced fasting glucose (-27.6 vs. -4.4 mg/dL, p = 0.03) . During the treatment period, adverse events were fewer in TTP399-treated subjects. No hypoglycemic events &lt;54mg/dL were observed in the TTP399 group compared with 2 subjects in the placebo group. Following insulin withdrawal, no significant differences in mean duration of IWT or beta-hydroxybutyrate (BOHB) at termination were observed between treatment groups (Figure 1A) . Serum bicarbonate was numerically higher and urine acetoacetate was qualitatively lower in TTP399-treated subjects (Figure 1A) . No patients on TTP399 met prespecified criteria for DKA while 43% of subjects on placebo did (Figure 1B, p = 0.03) .
These data suggest that TTP399 treatment improves glucose control with no increased risk of DKA.

Disclosure
K.Klein: None. S.C.Boeder: Consultant; Cecelia Health, Research Support; Dexcom, Inc., Lilly. J.L.Freeman: Employee; vTv Therapeutics, Stock/Shareholder; vTv Therapeutics. S.Madduri: None. E.R.Giovannetti: None. C.Valcarce: Employee; vTv Therapeutics. J.B.Buse: Consultant; Alkahest, Anji, AstraZeneca, Boehringer Ingelheim International GmbH, Cirius Therapeutics, Inc., Eli Lilly and Company, Fortress biotech, GentiBio, Glycadia, Glyscend, Janssen Pharmaceuticals, Inc., Mellitus Health, Moderna, Inc., Pendulum Therapeutics, Praetego, LLC, Stability Health, Valo, Zealand Pharma A/S, Other Relationship; Adocia, AstraZeneca, Eli Lilly and Company, Intarcia Therapeutics, Inc., MannKind Corporation, Novo Nordisk, Sanofi, Senseonics, vTv Therapeutics, Research Support; AstraZeneca, Dexcom, Inc., Eli Lilly and Company, Novo Nordisk, vTv Therapeutics, Stock/Shareholder; Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio Pharmaceuticals, Inc., Praetego, LLC, Stability Health. J.Pettus: Advisory Panel; Lilly, MannKind Corporation, Novo Nordisk, Sanofi, Consultant; Carmot Therapeutics, Inc., Diasome.

Funding
JDRF international
836-P: A Prebiotic Fiber Blend Improved Postprandial Glucose (PPG) and Time in Range (TIR) as Evaluated by Continuous Glucose Monitoring (CGM) in Healthy Subjects with Normal Glucose Tolerance
Authors: DAMMAN CHRISTOPHER J. , FRIAS JUAN PABLO , LEE MARTIN L. , RIKSE LARS , LAM WING SHUN , LAI REN-HAU , WASHINGTON MARC 
Published: May 2022

This open-label, pre-post, pilot study evaluated the impact of a prebiotic fiber blend (including green banana resistant starch & oat beta-glucan) on PPG and TIR measured by CGM (Abbott Freestyle Libre Pro) . Five healthy subjects (3M/2F; 41±7y, fasting glucose 92.2±10.9 mg/dL, BMI 23.9±3.2 kg/m2, mean+/-SD) consumed high glycemic index foods (e.g. cornflakes & rice milk) as the first meal of the day for 6 consecutive days followed by identical meals for 6 consecutive days with 7.5 grams of the prebiotic fiber blend. Addition of the prebiotic blend resulted in a significant 26.4% reduction in the baseline-adjusted 2-hr PP interstitial glucose (IG) area-under-the curve (Fig. 1a; 4125.9 ± 2468.9 vs. 3038.1 ± 1701.8 mg/dL, p=0.043) . Pooled subject 6-day % TIR (IG = 70-140 mg/dL) , % time above range (TAR, IG&gt;140 mg/dL) , and % time below range (TBR, IG&lt;70 mg/dL) showed a significantly higher % TIR (p=0.043) and lower % TBR (p=0.043) with the prebiotic blend (Fig. 1b) . This exploratory pilot study suggests the potential impact of a prebiotic fiber supplement as a complement to other dietary and pharmaceutical interventions for glycemic control. A randomized placebo controlled trial is currently underway to evaluate the impact of a full nutrition meal replacement shake with and without a similar fiber blend in persons with type 2 diabetes.

Disclosure
C.J.Damman: Advisory Panel; Evolve Biosystems, Employee; Uplifting Results Labs. J.Frias: Advisory Panel; Altimmune, Becton, Dickinson and Company, Eli Lilly and Company, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Merck & Co., Inc., Sanofi, Consultant; 89bio, Inc., Akero Therapeutics, Inc., Altimmune, Becton, Dickinson and Company, Carmot Therapeutics, Inc., Eli Lilly and Company, Novo Nordisk, Pfizer Inc., Sanofi, Research Support; Afimmune Limited, Akero Therapeutics, Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Carmot Therapeutics, Inc., Eli Lilly and Company, Intercept Pharmaceuticals, Inc., Ionis Pharmaceuticals, Janssen Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk, Pfizer Inc., Poxel SA, Sanofi, Speaker's Bureau; Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. M.L.Lee: Consultant; UR Labs. L.Rikse: Employee; Uplifting Results Labs. W.Lam: Employee; UR Labs. R.Lai: Employee; UR Labs. M.Washington: Employee; UR Labs (Uplifting Results) .
837-P: Hypoxemic COVID-Pneumonia, Diabetes Mellitus: Combination of Tailored Prednisone, Colchicine, Antithrombotics, Diuretic Improves Prognosis (CocAA-CoLa PLUS Study)
Authors: KEVORKIAN JEAN-PHILIPPE , MÉGARBANE BRUNO , FÉRON FLORINE , RIVELINE JEAN-PIERRE , MAUVAIS-JARVIS FRANCK , GAUTIER JEAN-FRANÇOIS 
Published: May 2022

In patients (pts) with diabetes mellitus (DM) , Covid-pneumonia mortality rate &gt;20% has been reported. A low fixed dose of intravenous dexamethasone (Dx) for days (RECOVERY study, 6 mg/d, i.e 0.5 mg/kg/d prednisone equivalent) has been shown to effectively reduce Covid-pneumonia mortality. In an observational study, prognosis was improved with an oral combination of prednisone fixed dose (1mg/kg/d) , direct anticoagulant/aspirin/colchicine/furosemide (DOAACF) . We hypothesized prednisone tailored doses driven by clinical evolution (extra 1mg/kg/d for every increase of O2 flow) added-on DOAACF for days would decrease morbi-mortality. In our monocentric, retrospective study (03.2020-05.2021) , pts with Covid-pneumonia requiring O2 out of the Intensive Care Unit (ICU) were included. According to the Physicians discretionary caring decisions, a control group (no corticoid) , a Dx group, an oral tailored prednisone ≥1mg/kg/d-DOAACF group were compared. The primary endpoint was Day 28 ICU requirement or mortality. Out of 3pts included for hypoxemic Covid-pneumonia, 132 pts had DM (43%) (control n = 28; Dx n = 46; tailored prednisone-DOAACF n = 58) : median age 69y; Males/Females 2.8; BMI 28 kg/m2; cardiovascular history 40%; median SpO2 at room air 92%; median maximal O2 flow 4L/min. Pts characteristics were non statistically different. Prednisone median dose (1.5mg/kg/d) and aspirin-colchicine-furosemide use were significantly higher in the tailored prednisone-DOAACF group in which events rate (12%) was significantly lower (control 50%, p = 0.0003, Dx 37%, p = 0.004) . In the tailored group, no statistical difference observed with pts without DM (13.3%, p = 1) . Out of the ICU, in pts with DM, a five oral drugs combination made of tailored prednisone ≥1mg/kg/d, anti-inflammatory, antithrombotics, diuretic improves hypoxemic Covid-pneumonia prognosis. A randomized trial is needed.

Disclosure
J.Kevorkian: None. B.Mégarbane: None. F.Féron: None. J.Riveline: None. F.Mauvais-jarvis: Consultant; Mithra Pharmaceutical. J.Gautier: Other Relationship; Novo Nordisk, Sanofi, Speaker's Bureau; Eli Lilly and Company.
84-OR: Responders to Neuropathic Pain Treatment Have Greater Target Engagement of Opioid Receptor Systems: A Resting State Functional Magnetic Resonance Imaging Study in Painful Diabetic Neuropathy
Authors: TEH KEVIN , SLOAN GORDON P. , WILKINSON IAIN D. , TESFAYE SOLOMON , SELVARAJAH DINESH 
Published: May 2022

Painful diabetic neuropathy (DN) is a common and distressing complication. New approaches are required to identify novel targets that will serve as a catalyst for future drug discovery programmes. We have demonstrated that responders to neuropathic pain treatment have greater functional connectivity between the insula cortex and the corticolimbic system compared to non-responders. Activity within these networks is mediated by endogenous opioid receptor systems and may hold clues to possible future treatment targets. Methods: 43 painful-DN subjects [responders (VAS&lt;4; n=29) and non-responders (VAS≥4; n=14) ] underwent detailed clinical and neurophysiological assessment, and RS-fMRI. Data analysis was performed using the NITRC Functional ConnectivityToolbox and SPM8 in MatLab. RS-fMRI data was masked and binarised using an opioid receptor atlas to restrict the analysis to the voxels with high receptor density. Subject-specific spatial maps of responders and non-responders were compared. Results: Compared to painful-DN non-responders, responders had greater functional connectivity between the corticolimbic system with the opioid receptor networks [F (2) (41) =43.53;intensity=128.7; R-amygdala beta=0.48; p-FDR&lt;0.0001; R-putamen beta=0.3; p-FDR&lt;0.0001; dorsal lateral prefrontal cortex beta=0.25; p-FDR=0.0002 and the posterior parietal cortex networks beta0.25; p-FDR=0.0002]. Conclusion: Painful DN treatment responders have better target engagement of opioid receptors systems compared to non-responders. This indicates that a functioning/intact descending pain inhibition network is crucial for a better pain response. Interventions targeted at this network could provide better pain relief in non-responders to neuropathic pain treatment.

Disclosure
K.Teh: None. G.P.Sloan: None. I.D.Wilkinson: None. S.Tesfaye: Advisory Panel; Astellas Pharma Inc., Bayer AG, Grünenthal Group, Nevro Corp., Wörwag Pharma GmbH & Co. KG, Speaker's Bureau; Eva Pharma, Pfizer Inc., Viatris Inc. D.Selvarajah: None.

Funding
National Institute of Health Research EME grant; European Foundation for the Study of Diabetes
840-P: Proof of Concept of I.P. Administered Neo-Islet (NI) T1DM Biotherapy: Omentum Becomes the New Endocrine Pancreas by Spontaneous Redifferentiation of In Vitro Dedifferentiated Islet Cells
Authors: GOOCH ANNA , CHOWDHURY SABIHA S. , WESTENFELDER CHRISTOF 
Published: May 2022

We published that treatment with allogeneic, species specific NIs, organoids of Mesenchymal Stromal Cells (MSCs) and culture expanded islet cells (ICs) functionally cured/improved the diabetic state in NOD mice, insulin dependent pet dogs, and NOD/SCID mice treated with dog or human NIs without requiring antirejection drugs or encapsulation devices (see also abstract this meeting) . Fig 1 summarizes the mode of action of NI therapy and experimental detail: Dedifferentiated ICs (∼ 6 PDLs) are incorporated into NIs and implanted into diabetic animals. They redifferentiate in vivo and normalize blood glucose levels as demonstrated by gene expression analysis on NIs retrieved from euglycemic diabetic mice at 21 weeks post administration. As seen in the right portion of the graph, gene expression levels of islet endocrine hormones in retrieved NIs are not significantly different from those of freshly isolated islets (log10 (RQ) &lt; ± 2) . These data demonstrate that although culture expansion of islet cells decreases endocrine gene expression as a function of PDLs, incorporation of ICs into NIs and implantation into a diabetic subject results in redifferentiation of the ICs, reestablishment of euglycemia, and restoration of islet hormone gene expression.

Disclosure
A.Gooch: Board Member; SymbioCellTech, LLC., Employee; SymbioCellTech, LLC., Stock/Shareholder; SymbioCellTech, LLC. S.S.Chowdhury: Employee; SymbioCellTech, LLC. C.Westenfelder: None.
842-P: A Novel Drug to Modulate Autoinflammation and Promote Glucose Control in Type 1 Diabetes Mellitus
Authors: WAGNER DAVID H. , VAITAITIS GISELA M. 
Published: May 2022

NOD mice are the accepted model for Type 1 Diabetes Mellitus (T1DM) Canine Diabetes (CD) demonstrates clinical outcomes identical to NOD and human T1DM. We described helper T cells that express the CD40 receptor, termed Th40 cells. In human T1DM Th40 cells expand significantly in number in peripheral blood prior to hyperglycemia; and respond to human islets. In NOD mice, Th40 cells increase first in the pancreatic lymph nodes, expand in number in the periphery prior to hyperglycemia, are the prominent T cell type detected in the pancreas during insulitis, and transfer diabetes to SCID recipients. Naturally occurring CD is insulin requiring and demonstrates the same clinical parameters as human disease. In a clinical pilot study using diabetic dogs we discovered significantly elevated Th40 cell numbers in PBMC compared to non-diabetic dogs (p &lt; 0.0001) . Th40 cell numbers may help predict risk of development of T1DM as a subset of “at-risk” pre-T1DM human subjects who developed T1DM showed elevated Th40 numbers. Using a novel approach to target CD40-mediated inflammation we created a series of small peptides. The lead candidate, OPT101, has an approved IND and completed Phase 1a human clinical trials establishing human safety profiles. OPT501, a canine version caused a rapid reduction in Th40 cell numbers in diabetic dogs. Daily insulin requirements were reduced on average by 75% and in 2 cases by 90%. Fructosamine, the canine equivalent of HbA1c, was reduced 40.2% on average with 3 subjects achieving normal range. All participants had significantly reduced daily blood glucose averages, and 3 subjects maintained normal glucose levels and time-in-range (TIR) increased to greater than 50%, and in some cases greater than 90%, from a previous TIR of 10%. All participants demonstrated increased c-peptide levels, a measure of restored beta cell function, after 6 weeks of treatment. Equivalent clinical outcomes have not been reported for any other drug candidate in veterinary or human T1DM trials.

Disclosure
D.H.Wagner: Other Relationship; Op-T, LLC. G.M.Vaitaitis: None.

Funding
National Institutes of Health (AI131784; AI128592)
843-P: Fortnight Intensive Treatment Strategy for Type 2 Diabetes
Authors: RAMANARAYANAN SHIVAA MOHAN 
Published: May 2022

According to ICMR IndiaB study, only 31% of Indians with type 2 diabetes (T2DM) have HbA1c ≤ 7 %. Hence, we strategize FIT (Fortnight intensive treatment) care to achieve an early Glycemic control that could effectively sustain over an extended period. In this study, individuals (N=107) with T2DM, aged &gt;18 years with HbA1c &gt;7% were subjected to a combination therapy of single or multiple OADs with or without insulin and short-term (14-days) insulinization. FBS (Fasting Blood sugar) and PPBS levels (Post prandial blood sugar) were measured on Day 0, 5, 14 and 90. Based on Day 0 estimates, individualized FIT care was initiated to achieve a target of FBS (100 – 130 mg/dL) and PPBS (180 – 190 mg/dL) . Treatment was intensified and optimized on Day 5 and 14, respectively. HbA1c between Day 0 and Day 90 was compared.On Day 0, mean FBS, PPBS and HbA1c values were 223.6 ± 69.2 mg/dL, 338± 68.5 and 10.1 ±1.9 %, respectively. Individuals using multiple (≥3) OADs and insulin therapy were 25% at enrolment and 75% during FIT care. After FIT care, there has been a significant reduction in FBS and PPBS (Figure 1) . By day 90, there is a significant (P&lt;0.0001) reduction of 3.13 % in the mean HbA1c levels compared to the levels during enrolment. About 64.5% had a sustained HbA1c% of ≤7. Figure 1: Effect of FIT care across visits In T2DM, FIT care’s glycemic control as early as day 5 and day 14 is beneficial for sustained glycemic control and reduction of treatment failure.

Disclosure
S.Ramanarayanan: None.
847-P: Assessment of Intestinal Microbiota in African-Americans Diabetics Thriving on or Not Tolerating This Drug
Authors: FAYFMAN MAYA , SRINIVASAN SHANTHI , UMPIERREZ GUILLERMO E. , BLANCO GERARDO , GEWIRTZ ANDREW , CHASSAING BENOIT 
Published: May 2022

Metformin is the broadly accepted the first-line medication for diabetes. Its use, however, is limited by gastrointestinal side effects, which occur in approximately 25% of patients. We performed a cross-sectional study assessing microbiota composition among African Americans (AA) with diabetes with or without metformin intolerance. Participants were stratified into three groups: 1) Intolerant (I) : history of metformin intolerance, not currently on metformin) ; 2) Partially intolerant (PI) : reporting GI symptoms and currently on metformin 3) Tolerant (T) : current metformin use with no GI symptoms. Rectal swab was collected and microbiota analyzed by amplification and sequencing of the V4 region of the 16s rRNA gene.Among 29 participants, mean age 59 ± 11, 58 % female, group I had greatest alpha diversity, followed by T and PI, although differences were not significant (I: 4.9; T: 4.2; PI: 3.9) . Mean difference in alpha diversity for I versus PI were 1.0 (95% CI -0.1, 2.1) and I versus T were 0.7 (95% CI -0.4, 1.8) . Phyla enrichment shown in figure.
Conclusion: This pilot study evaluated the role of microbiota in metformin intolerance among African Americans. We identify differences in alpha diversity and microbiota. Prospective studies are needed to assess the role of microbial diversity and dysbiosis in metformin-related gastrointestinal symptoms.

Disclosure
M.Fayfman: None. S.Srinivasan: None. G.E.Umpierrez: Research Support; AstraZeneca, Dexcom, Inc., Novo Nordisk. G.Blanco: None. A.Gewirtz: None. B.Chassaing: Advisory Panel; Nestlé Health Science, Consultant; Procter & Gamble, Qiagen.

Funding
P30-DK-111024